Recognized for its golden seashores and historic trams, Portugal fosters vital innovation. Whereas Portugal’s biotech and life sciences ecosystem will not be as massive and various as within the U.Ok., Switzerland, or Germany, it’s removed from merely an ‘rising’ one. Nonetheless, funding gloom must be overcome for it to succeed in its full potential, consultants say.
Life sciences and biotech in Portugal see sharp rise in recent times
The life science sector led to €29.7 billion ($34.41 billion) and €8.9 billion ($10.31 billion) in gross worth added in 2024, in line with a report by the Portuguese Commerce & Funding Company. On prime of that, the ecosystem consists of about 124,000 firms and has employed greater than 268,000 folks.
In accordance with Joana Branco, govt director of Biocant park within the metropolis of Cantanhede in Portugal, whereas the sector’s development has been “natural” over the previous twenty years, in recent times, a surge within the variety of firms and exports has been influenced by the nation’s pharmaceutical business.
Because the host of BIO-Europe Spring in Portugal final week, the nation’s life sciences and biotech sectors have been extra distinguished, because the occasion was partly an exhibit of the business within the area. With varied Portuguese biotech startups and universities in attendance, so was Branco’s Biocant, a nonprofit science and expertise park that homes practically 25 startups, a analysis middle, and UC-Biotech, the analysis and enterprise coaching infrastructure of the Heart for Neuroscience and Cell Biology.
“Bringing BIO-Europe Spring to Lisbon was one thing that we’ve been working quite a bit over time as a result of we felt like each time that we’d go to one among these conferences, folks would come to us saying, “what’s there in Portugal? I don’t know something in Portugal. Are you able to inform me extra about it?,” and we felt like we weren’t acknowledged for the potential that we have now,” mentioned Branco. “And so, it was so vital for us to deliver it right here so that individuals may have the chance to know our firms; additionally make it possible to smaller firms to be current at one among these occasions and see and companion and meet different colleagues. I might say that that is a crucial milestone for the biotech ecosystem in Portugal.”
The Mayor of Lisbon, Carlos Moedas, shared comparable emotions in regards to the occasion venturing to Portugal, stating that there’s “no higher place” on this planet for science, with 1.75% of its gross home product (GDP) devoted to analysis and growth.
However as Branco identified, a few many years in the past, the life science scene in Portugal informed a distinct story. Again then, biotech startups had been sparse – lower than 15 spanning the nation – and there was no enterprise capital (VC) dedicated to fortifying the life sciences within the area. In truth, it has been merely three years since Portugal gained its first ever VC earmarked for healthcare and biopharma, Biovance Capital, situated in Lisbon.
Portugal obtains first life science-focused VC
Albeit late to the celebration, a life science-focused VC means extra funding alternatives for the nation, which has witnessed its fair proportion of struggles with securing funding, extra so than different hubs in Europe. Fredilson Melo, communications supervisor of the Portuguese Bioindustry Affiliation (P-BIO), defined that it’s nonetheless higher late than by no means.
“In life science, issues are very unpredictable. They usually take plenty of time to flourish. You are attempting to develop a pharmaceutical product, and it takes round 15 years. So, the return is within the longer spectrum of time. That is very totally different from different areas, conventional areas the place folks make funding. So, it is advisable have folks that not solely have the understanding of how issues work, particularly in organic methods, but additionally how the logistics of doing analysis in life science works. Now, with a specialised VC fund for biotech, I believe it’s step one for others to see and possibly copy and broaden within the space of VC funding for biotech,” mentioned Melo.
For Portugal, funding has certainly been the most important hurdle, stifling analysis from being turned to innovation.
“Even when we’re bringing buyers from overseas, it’s nonetheless vital to have somebody for them to syndicate right here. So, in fact, funding remains to be one of many main causes that the businesses can have plenty of troubles when it comes to succeeding and shifting into the following section,” mentioned Branco.
That is additionally felt on the college stage, the place analysis is usually at its prime. Luís Silva, head of the Know-how Switch Workplace on the College of Coimbra, highlighted that entry to enterprise capital and cash to scale up applied sciences created by the Portuguese analysis and the scientific neighborhood is missing.
“You possibly can take the analysis till a sure level, however normally for the funding, you want, in some phases, like one or two or three million euros. When you don’t have this sort of funding, it’s very troublesome to succeed in sure ranges of maturity. One of many impacts is that it delays the interpretation of the applied sciences to the market quite a bit,” mentioned Silva.
“Historically, analysis in Portugal has been very, very robust. And over time, that could be a reflection on the variety of firms, however this translation to the business hasn’t been very environment friendly, which is one thing that we have now realized additional time. We attempt to work intently with the educational establishments additionally to attempt to pace up expertise switch.”
Owing to this, founders and researchers take their concepts elsewhere, exterior of Portugal, for an opportunity at scoring funding. However that’s nonetheless taxing as they might be competing with innovators all over the world for the identical pot, which has been drying up because the sector faces a funding drought globally.
“That’s why we’d like extra help and extra enterprise capital in Portugal to hurry issues up,” mentioned Silva.
And that’s not all. He added: “One of many large challenges is that Portugal is a small nation, and so we have now an extra problem to succeed in the worldwide market.”
Biocant and P-BIO: key gamers in bolstering Portugal’s life science and biotech sector
That’s the place college packages and organizations like Biocant and P-BIO in addition to authorities initiatives purpose to bridge the hole.
Melo mentioned: “What we attempt to present is a few coaching for our researchers who wish to be founders of latest spinouts. We attempt to develop totally different packages in phrases proof of ideas, prepare them learn how to pitch their expertise, and learn how to measure the financial worth.”
The college arrange a gene remedy analysis middle – the primary of its type – the GeneT: Centre of Excellence in Gene Remedy in Portugal, which bagged €38 million ($43.96 million) in European and nationwide funding for six years two years in the past. The purpose has been to develop gene therapies for extreme and untreatable uncommon ailments.
“Gene remedy is now receiving these funds to enhance the important mass on this subject and have their very own services,” mentioned Silva. “This gene remedy venture is in uncommon ailments. There are some uncommon ailments that they have been learning for a few years now that they wish to discover much more and probably create new spinouts or be part of collectively a novel platform to handle totally different uncommon ailments.”
One other R&D venture that the college has undertaken is in growing old. The college had spun off the Multidisciplinary Institute of Ageing (MIA-Portugal) six years in the past, the primary institute in Southern Europe specializing within the biology of ageing. This has been backed by Horizon Europe, the European Union flagship scientific analysis initiative to assist develop a sustainable society in Europe in addition to probably resolve public well being crises that embrace pandemic preparedness and most cancers.
Apart from funding, Portugal wish to grasp visibility. It has finished so with BIO-Europe Spring this yr, nevertheless it additionally has its annual BioMeet congress run by P-BIO to drive collaboration held in September.
“All our members collect there. Within the final couple of years, we have now gathered much more of worldwide gamers there as effectively,” mentioned Miguel Mondragão, well being venture supervisor at P-BIO.
Can new insurance policies make a distinction?
In the meantime, new insurance policies to encourage each scientists to construct applied sciences and funders to take a position, are being formed. A brand new invoice to guide scientific trials in Portugal is within the works. The most recent replace ensures that the framework totally aligns with EU Medical Trials Regulation (CTR) to harmonize it with the latter. This can draw drug builders situated exterior Portugal to maintain trials there.
Branco believes that working collectively as a number of entities inside a bigger ecosystem may help make a splash.
“Historically, analysis in Portugal has been very, very robust. And over time, that is a reflection on the variety of firms, however this translation to the business hasn’t been very environment friendly, which is one thing that we have realized additional time. We attempt to work intently with the educational establishments additionally to attempt to pace up expertise switch,” mentioned Branco.
Incentive schemes surrounding PhD analysis at biotechs have additionally been applied. The Fundação para a Ciência e a Tecnologia (FCT) referred to as on researchers to submit their proposals with a price range of €145 million ($167.64 million) in thoughts for this yr. Round 1,600 scholarships—50 greater than in 2025 – could be awarded to candidates, who can then go on to band with startups hospitals, museums, and NGOs. Melo thinks that this might assist alleviate the burden of paying for analysis at biotech firms.
Innovation not stalling; LXbio to publish section 2 outcomes
Because the file holder for the very best variety of patent purposes on the European Patent Workplace (EPO), with the biotech and healthcare sector grabbing between 30 and 40 patents, regardless of funding woes, it’s a constructive signal that innovation has not ceased. mRNA expertise pioneer BioNtech’s acquisition of Óbidos-based most cancers care firm CellmAbs’ preclinical antibody marked the primary billion-dollar deal within the life science sector for Portugal again in 2024. This got here after international CDMO Recipharm’s buyout of Oeiras-based GenIbet, which manufactured biologics, vectors, and microbiome therapies, in 2022.
Additional, antibody discovery-focused FairJourney Bio, located in Porto, simply launched its cryo-electron microscopy (cryo-EM) providers, an imaging approach that reveals the buildings of organic molecules, within the U.S. in January, placing the area on the map as soon as once more.
In the meantime, life science startups are making their approach too, though they haven’t crowded Portugal but. Lisbon-based LXbio is creating antibody and bacteriophage therapies to battle resistant infections, with its foremost focus on diabetic foot infections at current.
“Sufferers with infections within the late stage must have their leg eliminated, most instances. We created a bio resolution, an answer with a combination of phages for differing types of infections,” mentioned André Soares, enterprise developer at LxBio Prescribed drugs.
The cocktail of 5 totally different phages established security and tolerability in section 1 trials. Outcomes from a section 2b research, which trialed the drug in round 80 sufferers within the U.S. and India, will likely be introduced within the subsequent two weeks.
At BIO-Europe Spring 2026, LxBio was scouting for partnerships. Soares, like Branco and Melo, believes that a significant stymie to Portugal’s life science sector is funding, which results in an ecosystem that appears fragmented.
“You’ve gotten plenty of firms doing various good work. However as a result of the funding is so scarce, they’re principally attempting to outlive. They usually look exterior for partnership alternatives as a result of it’s the place the cash is,” mentioned Soares.
As Portugal clings on to its billion-dollar BioNtech deal as proof of its R&D expertise, organizing occasions like BIO-Europe Spring may see these collaborations replicated quickly.
Mondragão mentioned: “I imagine that this occasion (BIO-Europe Spring) can work as an excellent stepping stone to let the world know in regards to the Portuguese biotech ecosystem and the way it has been rising.”
With visibility hoped to draw capital, it may seize curiosity from buyers. Soares thinks that extra funding may diminish the fragmentation.
He mentioned: “Though we’re a small nation, we’re nonetheless the gateway to Europe coming from the U.S. and we are situated in a really good location. These days, you see that the connections to Lisbon and the connections to Portugal are growing. We’ve a really expert workforce and the price of dwelling, it’s nonetheless not similar to Central Europe. So, we expect this to be an excellent yr for us.”
Elevate your perspective with NextTech Information, the place innovation meets perception.
Uncover the newest breakthroughs, get unique updates, and join with a worldwide community of future-focused thinkers.
Unlock tomorrow’s developments right now: learn extra, subscribe to our publication, and turn into a part of the NextTech neighborhood at NextTech-news.com
